In recent months, scientists and policymakers around the globe have rallied together with one common goal: to eliminate Covid-19. Budgets have been revised to funnel money toward research, competitive barriers between scientists and companies have been lowered, and regulatory processes have been reworked to help safe and effective drugs and vaccines get to patients faster. It’s a time of urgency, of disruptive healthcare changes, and of creative problem-solving.

Trust is health’s most valuable player

COVID-19 has made clear that the politicization of health is incredibly dangerous; the health of billions of individuals is at stake, but so too is trust in pharmaceutical companies, in the scientific process, and in government and our regulatory agencies.

December 17, 2020 (Washington, D.C.) As Americans patiently await their turn for COVID-19 vaccination, a group of leading medical, health equity and public policy experts discussed and answered questions as part of a national briefing today about vaccines, including safety and efficacy; equitable access; and efficient distribution.

US regulators have authorised the first coronavirus vaccine for emergency use, marking an inflection point in the pandemic and kicking off what's set to be the largest vaccination campaign in US history.